Variant Perception

Where We Disagree With the Market

The market is paying ~1.0× book and ~12× FY2025 P/E for an earnings recovery the cash statement explicitly refused to confirm — and our evidence says that gap is structural, not a timing artifact. Consensus, visible in a +154% twelve-month rally, trade-press coverage naming Mirae as a "CXMT-tier" Korean supplier, and a controlling-shareholder ₩6.5B injection read as commitment, has effectively underwritten the FY2025 P&L as the start of a structural earnings step-up. We disagree on three measurable points: cash conversion is a five-year structural pattern (cumulative net income ₩0.7B vs FCF −₩49.8B), the YILINING win was a price concession (ATE ASP cut 49% from ₩978M to ₩502M per unit), and the unexplained ₩30.8B PP&E reclassification sits unpriced inside a coverage vacuum. The single most important resolving signal is the Q2 FY2026 operating cash-flow line in the mid-August DART quarterly business report.

Variant Perception Scorecard

Variant strength is high but not maximal because the three disagreements share one underlying resolution — the Q2 and Q3 FY2026 cash flow line — and a single clean print could refute all three at once. Consensus clarity is only moderate because there is no published sell-side coverage; we are reading consensus off price action, trade-press framing, and how the tape reacted to the ₩14B and ₩10B contracts disclosed in late 2025. Evidence strength is high because the five-year cumulative cash gap, the per-unit ASP series, and the FY2024 PP&E unwind are all observable in DART filings and would survive a hostile institutional review. Time to resolution is short — the Q2 FY2026 quarterly business report lands roughly 84 days from now and is the single observable that decides whether the FY2025 print was a working-capital timing artifact or the structural signature of a price-taker.

Consensus Map

The five issues above are not equally consensus. The earnings-durability and customer-durability assumptions are the strongest — they are visible in the price level, the trade-press framing, and the bull anchor. The forensic profile and parent-commitment readings are weaker; they look more like "absence of disconfirmation" than active conviction. We focus the disagreement ledger on the three issues where consensus is clear, observable, and material to a PM's underwriting decision.

The Disagreement Ledger

Disagreement #1 — cash conversion. Consensus, anchored in the +154% rally and Bull's ₩42,000 anchor at 12× FY2026E NI, treats the FY2025 cash flow statement as a quirk. Our evidence is that the five-year cumulative cash gap is structural — cumulative net income ₩0.7B sits against cumulative FCF of −₩49.8B, financed by ₩43.6B of equity and CB issuance — and FY2025 widened the gap rather than closing it. If we are right, the market is paying an earnings multiple on an income statement that has not produced cash in any full cycle, and the equity needs a book-floor anchor (0.4-0.6× book) rather than an earnings multiple. The cleanest disconfirming signal is one Q2 FY2026 OCF print of ≥₩2B against revenue ≥₩18B with no new financing — that would refute the structural-gap reading immediately.

Disagreement #2 — ASP and the CXMT-supplier narrative. Consensus, visible in the November-December rally on the ₩14B and ₩10B contracts and the February 2026 trade-press CXMT coverage, treats the YILINING relationship as a qualifying win that delivers a durable ₩50B+ revenue base. Our evidence is that ATE per-unit revenue collapsed from ₩978M to ₩502M (−49%) in a single year — the operational signature of a price-taker, not a moat-protected vendor. If we are right, the bull case has no support even if revenue holds, because incremental volume at lower price erodes the margin assumption embedded in the ₩42,000 anchor. The cleanest disconfirming signal is FY2026 ATE revenue ÷ units shipped: a print above ₩700M/unit with stable volume validates the franchise read; a print at or below ₩500M confirms the price-taker.

Disagreement #3 — the FY2024 PP&E reclassification is unpriced. Consensus has not formed because nobody is looking — there is no sell-side, no governance score, and the ₩30.8B PP&E movement requires side-by-side reading of two annual balance sheets to surface. Our evidence is that the line moved off PP&E in FY2025 without a matching cash receipt or disclosed disposal, leaving an audit-grade open question on the largest single asset movement in the five-year file. If we are right, the rally has been pricing earnings on a balance sheet whose composition is unverified, and any (정정) amendment or auditor change becomes the trigger for a forensic short. The cleanest disconfirming signal is a clean FY2025 audited footnote that names an arm's-length counterparty with cash receipts visible; the cleanest confirming signal is a related-party identification or a 정정 filing.

Disagreement #4 — the Nexturn injection direction. Consensus reads ₩6.5B flowing into Mirae as a parent vote of confidence; our evidence is that the chain above Mirae booked combined FY2025 losses of ₩23.6B, the injection landed exactly when Mirae's OCF turned negative, and the long-run incentive of a loss-making controlling chain is to harvest a cash-positive subsidiary, not to fund it. If we are right, the 2026-07-27 5-for-1 forward split is the optics-reset moment to watch for a follow-on capital action — exactly the pattern that surrounded the July-2025 16:1 reverse split. The cleanest disconfirming signal is two consecutive fiscal years with flat share count and no new CB issuance; the cleanest confirming signal is any new equity-linked filing inside ±90 days of the forward split.

Evidence That Changes the Odds

The eight items above are not equally load-bearing. The first three — five-year cash conversion, ASP collapse, and PP&E reclassification — are the spine of the variant view; each is independently observable and each has a defined resolution window inside the next two quarterly reports. The remaining five are corroborating; they harden the case but a clean Q2 print could refute the lead three regardless.

How This Gets Resolved

The six signals above are ranked by decision value. The Q2 FY2026 OCF print sits at the top because a single number from one disclosure can refute three of the four ledger items simultaneously: it tests the cash-conversion thesis (Disagreement #1), it constrains how much receivables build can be attributed to YILINING ramp timing (Disagreement #2), and the absence of a concurrent capital-action filing tests the parent-commitment thesis (Disagreement #4). The PP&E footnote signal sits at #3 because the audit review is the only forum where the FY2024 movement gets independently sourced, but the resolution window is longer. The BIS signal is binary and uncorrelated with operating evidence; it sits at #6 because no operating improvement offsets it and no operating deterioration accelerates it.

What Would Make Us Wrong

The cleanest way we are wrong is if the FY2025 cash gap really was a working-capital timing artifact of the late-year China shipment schedule, and Q2 FY2026 prints positive OCF on stable revenue. That outcome would not refute the five-year cumulative cash gap, but it would shift the question from "structural price-taker" to "cycle-leveraged industrial in an up-leg," and the multiple the market is paying would have an economic basis. If the same Q2 also shows YILINING revenue share drifting toward 45-50% with a non-Yiling counterparty appearing in the disclosure stream, two of the four ledger items break at once and the variant view collapses to the forensic profile alone — which is interesting but not investable on its own.

The second way we are wrong is on ASP. A 49% per-unit decline in one year is consistent with both a price-taker concession and a one-time mix shift toward simpler legacy package types as Mirae enters a new buyer's footprint. If FY2026 segment disclosure shows the ASP normalising back toward ₩700M as the mix re-balances, the price-taker reading weakens materially. That is a real path — Mirae is a small vendor at the start of a new customer relationship, and entry-level package types do command lower per-unit pricing across the industry — and we do not have enough years of YILINING-specific disclosure to rule it out.

The third way we are wrong is the PP&E footnote. A clean K-IFRS sale-leaseback with an arm's-length counterparty and visible cash receipts in the FY25 audited statements would resolve the cost-shift signal entirely. Sale-leasebacks are common in capital-intensive industrials and the right-of-use reclassification under K-IFRS 16 is mechanically what the FY24/FY25 PP&E shape looks like. We are willing to be wrong on this one signal because the alternative explanations are routine and the audit window for verification is short.

The fourth way we are wrong is on the controlling chain. Nextern Roll Korea has now injected capital into Mirae once, and there is a real (if narrow) scenario where the chain is funded externally and continues to support the operating subsidiary through the next cycle. In that scenario, Mirae's capital-allocation history is a closed chapter as of January 2026 and the next downturn is the first one underwritten by a committed parent rather than the market.

The first thing to watch is the Q2 FY2026 operating cash flow line in the DART 분기보고서 expected around 2026-08-14 — a positive OCF print on revenue at or above ₩18B with no concurrent capital filing refutes three of the four disagreements at once; another quarter of NI-positive, OCF-negative confirms the structural reading we are arguing here.